Gastric Cancer Forecast and Market Analysis to 2024

  • ID: 3797409
  • Report
  • 334 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Gastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably high in East Asia, China, Eastern Europe, and Latin America, whereas the disease is no longer as common in North America and Western Europe. Globally, there has been a steady decline in incidence over the past 50 years. This is mostly attributable to the decline in prevalence of H. pylori infections, a decline in tobacco use, and improvements in food preservation and diet.

Market Snapshot
  • The gastric cancer market is projected to reach $2.1bn in value by 2026, with growth driven by immunotherapies.
  • Cyramza plays an important role in the second-line treatment of metastatic and distant relapse gastric cancer.
  • Despite declining incidence proportions, the number of cases is forecasted to increase and prognosis remains poor.
  • Cyramza’s dominance in second-line advanced gastric cancer is being challenged as immunotherapies enter the market.
  • Bavencio will target the maintenance setting in order to avoid direct competition with established immunotherapies.
  • Access restrictions are moderate in gastric cancer and GIST.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: GASTRIC CANCER (Published on 22 December 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: ABRAXANE
PRODUCT PROFILE (LATE STAGE): BAVENCIO
PRODUCT PROFILE: CYRAMZA
PRODUCT PROFILE: HERCEPTIN
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE: OPDIVO
PRODUCT PROFILE (LATE STAGE): ANDECLAXIMAB
PRODUCT PROFILE (LATE STAGE): APATINIB

TREATMENT: GASTRIC CANCER (Published on 12 December 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU (Published on 11 December 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
METHODOLOGY
FORECAST
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: GASTRIC CANCER (Published on 22 December 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: ABRAXANE
PRODUCT PROFILE: CYRAMZA
PRODUCT PROFILE: HERCEPTIN
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE: OPDIVO

GASTRIC CANCER PRICING, REIMBURSEMENT, AND ACCESS (Published on 28 November 2017)
GASTRIC CANCER PRICING, REIMBURSEMENT, AND ACCESS
PIPELINE: GASTRIC CANCER (Published on 22 December 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): BAVENCIO
PRODUCT PROFILE (LATE STAGE): ANDECLAXIMAB
PRODUCT PROFILE (LATE STAGE): APATINIB

List of Figures
Figure 21: Herceptin for gastric cancer - SWOT analysis
Figure 22: Drug assessment summary of Herceptin for gastric cancer
Figure 23: Drug assessment summary of Herceptin for gastric cancer
Figure 24: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 25: Keytruda for gastric cancer - SWOT analysis
Figure 6: Price sources and calculations, by country
Figure 26: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 8: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 29: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 10: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 31: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 32: Apatinib for gastric cancer - SWOT analysis
Figure 33: Drug assessment summary of apatinib for gastric cancer
Figure 34: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 35: Stage distribution of gastric cancer patients, by country
Figure 38: Top three regimens used in the adjuvant treatment of Stage III gastric cancer patients, by country
Figure 17: Drug assessment summary of Keytruda for gastric cancer
Figure 18: Drug assessment summary of Keytruda for gastric cancer
Figure 39: Percentage of Stage IV gastric cancer patients receiving each treatment type, by country
Figure 20: Opdivo for gastric cancer - SWOT analysis
Figure 40: Percentage of Stage IV gastric cancer patients who progress from first- to second-line therapy or from second- to third-line therapy, by country
Figure 41: Top three regimens used for second-line treatment of Stage IV gastric cancer patients, by country
Figure 23: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 42: Top three regimens used for first-line treatment of local relapse gastric cancer, by country
Figure 25: Drug assessment summary of andecaliximab for gastric cancer
Figure 26: Drug assessment summary of andecaliximab for gastric cancer
Figure 27: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 44: Top three regimens used for first-line treatment of distant relapse gastric cancer, by country
Figure 29: Drug assessment summary of apatinib for gastric cancer
Figure 30: Drug assessment summary of apatinib for gastric cancer
Figure 45: Top three regimens used for second-line treatment of distant relapse gastric cancer, by country
Figure 32: Percentage of Stage 0-II gastric cancer patients receiving each type of treatment, by country
Figure 47: Abraxane for gastric cancer - SWOT analysis
Figure 49: Drug assessment summary of Abraxane for gastric cancer
Figure 50: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 51: Cyramza for urothelial bladder cancer - SWOT analysis
Figure 37: Percentage of local relapse gastric cancer patients receiving each treatment type, by country
Figure 54: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 55: Herceptin for gastric cancer - SWOT analysis
Figure 40: Percentage of distant relapse gastric cancer patients receiving each treatment type, by country
Figure 58: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 59: Keytruda for gastric cancer - SWOT analysis
Figure 59: Drug assessment summary of Keytruda for gastric cancer
Figure 44: Trends in incident cases of gastric cancer in the US, Japan, and five major EU markets, 2016-36
Figure 60: Drug assessment summary of Opdivo for gastric cancer
Figure 61: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 63: Drug assessment summary of Bavencio for gastric cancer
Figure 64: Drug assessment summary of Bavencio for gastric cancer
Figure 65: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 68: Drug assessment summary of andecaliximab for gastric cancer
Figure 71: Drug assessment summary of apatinib for gastric cancer
Figure 72: Drug assessment summary of apatinib for gastric cancer
Figure 73: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 54: Opdivo for gastric cancer - SWOT analysis
Figure 55: Drug assessment summary of Opdivo for gastric cancer
Figure 56: Drug assessment summary of Opdivo for gastric cancer
Figure 57: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 58: Bavencio for gastric cancer - SWOT analysis
Figure 59: Drug assessment summary of Bavencio for gastric cancer
Figure 60: Drug assessment summary of Bavencio for gastric cancer
Figure 61: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 62: Andecaliximab for gastric cancer - SWOT analysis
Figure 63: Drug assessment summary of andecaliximab for gastric cancer
Figure 64: Drug assessment summary of andecaliximab for gastric cancer
Figure 65: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 66: Apatinib for gastric cancer - SWOT analysis
Figure 67: Drug assessment summary of apatinib for gastric cancer
Figure 68: Drug assessment summary of apatinib for gastric cancer
Figure 69: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Gastric cancer market value across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 2: Gastric cancer patient population in the US, Japan, and five major EU markets, by country, 2017-26
Table 3: Gastric cancer market value across the US, Japan, and five major EU markets, by class ($m), 2017-26
Table 4: Sales of PD-1/PD-L1 inhibitors for gastric cancer across the US, Japan, and five major EU markets, by brand ($m), 2017-26
Table 5: Summary of drug classes and molecules included in the author’s gastric cancer patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in gastric cancer across the US, Japan, and five major EU markets, 2017-26
Table 8: Estimated launch dates of key pipeline products and marketed brands in gastric cancer across the US, Japan, and five major EU markets, 2017-26
Table 9: Medical oncologists and gastroenterologists surveyed for the gastric cancer primary research study, 2017
Table 10: Abraxane drug profile
Table 11: Abraxane pivotal trial data in gastric cancer
Table 32: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 34: Opdivo Phase III trials in gastric cancer
Table 14: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 15: Abraxane patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 16: Bavencio drug profile
Table 17: Bavencio Phase III trials in gastric cancer
Table 18: Bavencio Phase III trial data in gastric cancer
Table 19: Bavencio early-phase data in gastric cancer
Table 20: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 21: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 22: Cyramza drug profile
Table 23: Cyramza pivotal trial data in gastric cancer
Table 24: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 25: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 26: Herceptin drug profile
Table 27: Herceptin pivotal trial data in gastric cancer
Table 28: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 29: Herceptin patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 30: Keytruda drug profile
Table 31: Keytruda pivotal trial data in gastric cancer
Table 32: Keytruda Phase III trials in gastric cancer
Table 33: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 34: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 35: Opdivo drug profile
Table 36: Opdivo pivotal trial data in gastric cancer
Table 37: Opdivo Phase III trials in gastric cancer
Table 38: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 39: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 40: andecaliximab drug profile
Table 41: andecaliximab Phase III trials in gastric cancer
Table 42: andecaliximab early-phase data in gastric cancer
Table 43: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 44: Andecaliximab patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 45: apatinib drug profile
Table 46: apatinib Phase III trials in gastric cancer
Table 47: apatinib early-phase data in gastric cancer
Table 48: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 49: Apatinib patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 50: Medical oncologists and gastroenterologists surveyed for the gastric cancer primary research study, 2017
Table 51: Gastric cancer five-year survival rates in the US, by stage at diagnosis
Table 52: TNM classification, by stage at diagnosis
Table 53: Incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016-36
Table 54: Gastric cancer International Statistical Classification of Diseases topography codes
Table 55: Cancer registry databases used as a source of gastric cancer incidence data, by country
Table 56: Data sources used to segment incident gastric cancer cases by AJCC stage, by country
Table 57: Incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016-36
Table 58: Age- and gender-specific incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016
Table 59: Proportion and number of incident cases of gastric cancer in the US, Japan, and five major EU markets, by AJCC stage at diagnosis and country, 2016
Table 60: Proportion and number of incident cases of gastric cancer in the US, Japan, and five major EU markets, by anatomical tumor location and country, 2016
Table 74: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 62: Profiled key marketed drugs for gastric cancer
Table 63: Abraxane drug profile
Table 64: Abraxane pivotal trial data in gastric cancer
Table 65: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 66: Abraxane patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 81: Bavencio Phase III trials in gastric cancer
Table 68: Cyramza pivotal trial data in gastric cancer
Table 83: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 70: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 71: Herceptin drug profile
Table 72: Herceptin pivotal trial data in gastric cancer
Table 73: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 74: Keytruda drug profile
Table 75: Keytruda pivotal trial data in gastric cancer
Table 76: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 77: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 78: Opdivo drug profile
Table 79: Opdivo pivotal trial data in gastric cancer
Table 80: Opdivo Phase III trials in gastric cancer
Table 81: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 82: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 83: Profiled pipeline products in development for gastric cancer
Table 84: Bavencio drug profile
Table 85: Bavencio Phase III trials in gastric cancer
Table 86: Bavencio Phase III trial data in gastric cancer
Table 87: Bavencio early-phase data in gastric cancer
Table 88: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 89: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 90: andecaliximab drug profile
Table 91: andecaliximab Phase III trials in gastric cancer
Table 92: andecaliximab early-phase data in gastric cancer
Table 93: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 94: Andecaliximab patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Table 95: apatinib drug profile
Table 96: apatinib Phase III trials in gastric cancer
Table 97: apatinib early-phase data in gastric cancer
Table 98: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 99: Apatinib patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll